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Measures in COPD StudyBACKGROUND: Aspirin use in COPD has been associated with reduced all-cause mortality in
meta-regression analysis with few equivocal studies. However, the effect of aspirin on COPD
morbidity is unknown.
METHODS: Self-reported daily aspirin use was obtained at baseline from SPIROMICS participants
with COPD (FEV1/FVC < 70%). Acute exacerbations of COPD (AECOPD) were prospectively
ascertained through quarterly structured telephone questionnaires up to 3 years and categorized as
moderate (symptoms treated with antibiotics or oral corticosteroids) or severe (requiring ED visit
or hospitalization). Aspirin users were matched one-to-one with nonusers, based on propensity
score. The association of aspirin use with total, moderate, and severe AECOPD was investigated
using zero-inflated negative binomial models. Linear or logistic regression was used to investigate
the association with baseline respiratory symptoms, quality of life, and exercise tolerance.
RESULTS: Among 1,698 participants, 45% reported daily aspirin use at baseline. Propensity score
matching resulted in 503 participant pairs. Aspirin users had a lower incidence rate of total
AECOPD (adjusted incidence rate ratio [IRR], 0.78; 95% CI, 0.65-0.94), with similar effect for
moderate but not severe AECOPD (IRR, 0.86; 95% CI, 0.63-1.18). Aspirin use was associated
with lower total St. George’s Respiratory Questionnaire score (b, –2.2; 95% CI, –4.1 to –0.4),
reduced odds of moderate-severe dyspnea (modified Medical Research Council questionnaire
score $ 2; adjusted odds ratio, 0.69; 95% CI, 0.51-0.93), and COPD Assessment Test score (b,
–1.1; 95% CI, –1.9 to –0.2) but not 6-min walk distance (b, 0.7 m; 95% CI, –14.3 to 15.6).
CONCLUSIONS: Daily aspirin use is associated with reduced rate of COPD exacerbations, less
dyspnea, and better quality of life. Randomized clinical trials of aspirin use in COPD are
warranted to account for unmeasured and residual confounding.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969344; URL: www.clinicaltrials.gov
CHEST 2019; 155(3):519-527KEY WORDS: acute exacerbation of chronic bronchitis; antiplatelet drugs; COPD; dyspnea;
quality of lifeAFFILIATIONS: From the Division of Pulmonary and Critical Care
Medicine (Drs Fawzy, Putcha, Wise, and Hansel), Johns Hopkins
School of Medicine, Baltimore, MD; the Department of Medicine (Drs
Aaron and Barr), Columbia University College of Physicians and
Surgeons, New York, NY; the Department of Medicine (Dr Bowler),
National Jewish Medical and Research Center, Denver, CO;
-min walk distance; AECOPD = acute 
= COPD Assessment Test; IRR = inci-
ltidetector row CT; mMRC = modified 
RQ = St. George’s Respiratory Ques-
populations and Intermediate Outcome 
Pharmacologic therapy for COPD consists of treatment
using combination inhaler therapy focused on
bronchodilation and decreasing pulmonary
inflammation. However, the systemic manifestations of
COPD, including systemic inflammation, are
inadequately addressed by current therapies. Inhaled
corticosteroids have not been shown to reduce circulating
inflammatory biomarkers.1 Chronic macrolide
antibiotics, which have antiinflammatory and
immunomodulatory properties in addition to
antibacterial effects, have been associated with fewer acute
exacerbations of COPD (AECOPD) among patients with
severe COPD and a history of exacerbations; however, use
has been limited by concern for antibiotic resistance and
significant hearing loss.2,3 Likewise, the
phosphodiesterase-4 inhibitor roflumilast reduced the
rate of COPD exacerbations only in patients with chronic
bronchitis and severe disease, and its use has been limited
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C-reactive protein (CRP),6 were ineffective in reducing
the exacerbation rate among patients with moderate-to-
severe COPD in a clinical trial.7
Aspirin, which inhibits platelet activity by blocking
conversion of arachidonic acid and has both direct and
indirect antiinflammatory properties, has been
associated with reduced all-cause mortality among
patients with COPD in most,8-12 but not all,13,14
previous studies. Aspirin has also been associated with
reduced odds of mechanical ventilation and shorter
hospital stay during AECOPD and reduced emphysema
progression in the general population.9,15 To our
knowledge, whether aspirin use is associated with COPD
morbidity has not previously been explored. This study
investigates the association of aspirin use with
AECOPD, respiratory symptoms, and quality of life,
using a large, well-characterized observational cohort.
Materials and Methods
The Subpopulations and Intermediate Outcome Measures in COPD
Study (SPIROMICS) is an observational cohort study that enrolled
current and former smokers ($ 20 pack-years) and nonsmokers (#
1 pack-year) aged 40 to 80 years from 12 clinical sites in the United
States, recruited from 2010 to 2015 and followed up to 36 months
with the goal of identifying intermediate outcome measures that
predict long-term clinical end points of morbidity.16 Participants
with COPD (postbronchodilator ratio of FEV1 to FVC < 70%) were
selected for this analysis. Participants were specifically asked at
baseline whether they were currently taking a daily aspirin (yes/no).
Information about dose, adherence, and duration of therapy was not
available and therefore not accounted for in the analysis.
Outcomes
Respiratory events, ED visits, and hospitalizations were ascertained
through structured telephone questionnaires administered quarterly
throughout follow-up. The primary outcome of interest is total
number of moderate or severe AECOPD, which was subdivided into
moderate AECOPD (defined as respiratory symptoms treated with
antibiotics or oral corticosteroids or requiring physician’s office or
urgent care visit) and severe AECOPD (defined as respiratory
symptoms requiring an ED visit or hospitalization). Secondary
outcomes of interest included baseline COPD health status based on
total COPD Assessment Test (CAT) score,17 moderate-severe
dyspnea defined as modified Medical Research Council (mMRC)
questionnaire18 score $ 2, exercise capacity based on 6-min walk
distance (6MWD) in meters,19 and respiratory-specific quality of life
based on the St. George’s Respiratory Questionnaire (SGRQ) score.20
Propensity Score and Matching
A propensity score—the predicted probability that a participant reports
taking daily aspirin at baseline—was obtained for each participant,
using a nonparsimonious multivariable generalized mixed logistic
regression model with random intercepts for study site. The model
included age (continuous), sex, race (African American vs other),
educational achievement (< high school vs $ high school), percent
predicted postbronchodilator FEV1 (continuous),
21 smoking status
(current smoker based on self-report or, if unavailable, exhaled
carbon monoxide > 6 parts per million vs former smoker),22
presence of hypertension, coronary heart disease (history of coronary
artery disease, heart attack, or angina; coronary heart disease),
congestive heart failure, diabetes, stroke, body mass index
(categorical: underweight [< 18.5 kg/m2] vs normal/overweight [18.5
to < 30 kg/m2] vs obese [$ 30 kg/m2]), anemia23 (dichotomous,
using sex-specific cutoffs of hemoglobin), oxygen use, statin use,
b-blocker use, and inhaler therapy (long-acting antimuscarinic, long-
acting b-agonist, or inhaled corticosteroid) use during the preceding
3 months.
Aspirin users were then matched one-to-one without replacement with
nonusers based on the propensity score, using a caliper width equal to
0.2 times the standard deviation of the logit of the propensity score.24,25
For longitudinal analysis of the primary outcome of interest, only
participants who had accrued follow-up time and had nonmissing
exacerbation data were eligible to be matched. For cross-sectional
analysis of secondary outcomes, participants with data for any
outcome regardless of subsequent follow-up were rematched on the
basis of propensity score, using the above method. Analysis of each
secondary outcome included only participant pairs where both
participants had nonmissing data for that outcome.
Statistical Analysis
Baseline characteristics and health-related variables were compared
between aspirin users and nonusers in the unmatched and
propensity score-matched samples, using the c2 test for proportions
and the Student t test or Kruskal-Wallis test for continuous variables
to evaluate means and medians respectively. Subsequent analyses
(except sensitivity analyses) were performed in the matched sample.
Crude exacerbation rates were calculated as number of AECOPD per
person-year of follow-up and compared between aspirin users and
nonusers with a Student t test. Median follow-up time was compared
between the groups, using the Kruskal-Wallis test. Unconditional
zero-inflated negative binomial models accounting for total follow-up
time as an offset variable with FEV1 as the zero inflation variable
were constructed to investigate the association of aspirin use with
total AECOPD, moderate AECOPD, and severe AECOPD separately
controlling for all covariates that were included in the propensity
score model to account for residual confounding.26,27 Several
sensitivity analyses were performed to determine whether results
were robust to different modeling strategies in the unmatched
sample: (1) fully adjusted zero-inflated negative binomial regression,
(2) bivariate zero-inflated negative binomial model adjusted forpropensity score as a continuous variable, and (3) inverse probability
of the treatment weights.28,29 Furthermore, to minimize the effect of
possible changes in aspirin use over time, death, or loss to follow-up,
the association of aspirin use with number of AECOPD within the
first year of follow-up was investigated using a similar model
(without the offset variable) among propensity score-matched
participants who had both accrued at least 365 days of follow-up.
Since previous systemic therapies in COPD demonstrated clinical
benefit among patients with more severe obstruction or chronic
bronchitis,2-4 effect modification of the association between aspirin
use and AECOPD by disease severity (mild/moderate vs severe) and
presence of chronic bronchitis as defined by either the classic or
alternative (SGRQ) definition30 was explored by multiplicative
interaction and by calculating stratum-specific estimates.
Furthermore, effect modification by emphysema burden at baseline
was explored in light of recent evidence that aspirin use reduced
emphysema progression in a general population cohort.15 Whole-
lung multidetector row CT (MDCT) scans were performed at
baseline for both coached total lung capacity and coached residual
volume. Emphysema-like lung was calculated on the basis of the
percentage of total lung voxels < –950 Hounsfield units at total lung
capacity.31 Effect modification based on the presence of emphysema
(< 5% vs $ 5%) and emphysema severity (continuous percent
emphysema) was evaluated, including MDCT scanner model as an
additional covariate. Finally, in order to investigate the possibility of
differential misclassification of cardiovascular events as AECOPD,
effect modification by the presence of cardiometabolic phenotype ($
2 cardiac/metabolic comorbidities: hypertension, coronary heart
disease, congestive heart failure, stroke, diabetes, and obesity)23 was
also explored.
In the cross-sectional analysis of secondary outcomes, unconditional
multivariable linear regression was used to investigate the association
of aspirin use with baseline 6MWD, total CAT and SGRQ scores
while unconditional multivariable logistic regression was used to
investigate the association of aspirin use with moderate-severe
dyspnea (mMRC score $ 2). Participants who were missing data on
an outcome were removed along with their matched pair in order to
maintain a balanced sample.
Analyses were conducted with SAS 9.4 (SAS Institute). The threshold
of significance for main effects was P < .05, while interaction terms
were considered significant at P < .1.32 SPIROMICS was approved
by the institutional review board at each center (e-Table 1), and all
participants provided written informed consent (ClinicalTrials.gov:
NCT01969344).Results
Among 1,843 SPIROMICS participants with COPD, 
1,749 (95%) had complete data on aspirin use and all 
relevant covariables for propensity score calculation 
(Fig 1). Of the 1,698 participants (92%) who accrued 
follow-up time and had nonmissing exacerbation data, 
764 (45%) reported using aspirin daily at baseline. 
Compared with nonusers, aspirin users were 
significantly older; more likely to be male, white, and 
obese; less likely to be smokers; had better lung 
function but more cardiovascular comorbidities; and 
were more likely to use cardiovascular medications 
(Table 1). Matching resulted in 503 pairs ofparticipants with all baseline characteristics balanced
between aspirin users and nonusers (Table 1). Overall,
the matched sample participants were on average
66.5 years old, had an average postbronchodilator
FEV1 of 62% predicted, were male more often than
female (58%) and white more often than black (88%),
and with fewer than two cardiovascular
comorbidities (62%). At baseline, the sample consisted
of 30% current smokers and 23% home oxygen users,
with 43% reporting statin use, 48% reporting
inhaled corticosteroid use, and 58% reporting long-
acting bronchodilator use during the previous
3 months.
39 Missing aspirin use data
1,804 with COPD and aspirin data
1,749 with complete covariates
for propensity score calculation
33 No follow-up time
1,698 Eligible for matching
764 Aspirin users 934 Aspirin non-users
503 Aspirin users 503 Aspirin non-users
Propensity Score Match
18 Missing exacerbation data
55 Missing Covariates
     13 Race or Education
     21 Comorbidities
     21 Medications
1,843 SPIROMICS participants with COPD
Figure 1 – CONSORT diagram of SPIROMICS participants. 
CONSORT ¼ Consolidated Standards of Reporting Trials; 
SPIROMICS ¼ Subpopulations and Intermediate Outcome Measures in 
COPD Study.Association of Aspirin Use With COPD 
Exacerbation Rate
In the propensity score-matched sample participants 
taking aspirin were monitored for a median of 2.7 years 
(Q1-Q3, 1.8-3.0 years) compared with 2.6 years (Q1-Q3, 
1.8-3.0 years) for aspirin nonusers (Kruskal-Wallis P ¼ 
.15). One-half of the sample did not report any 
exacerbations during follow-up, with an overall crude 
exacerbation rate of 0.58  1.0 (0.40  0.73 [moderate 
AECOPD] and 0.19  0.56 [severe AECOPD]) per 
person-year. Comparison of crude AECOPD rates by 
aspirin use is displayed in Table 2.
In adjusted analysis of the matched sample, aspirin users 
had an estimated 22% lower incidence rate of total 
AECOPD (incidence rate ratio [IRR], 0.78; 95% CI, 
0.65-0.94), which was similar to the reduction in 
moderate AECOPD (IRR, 0.75; 95% CI, 0.61-0.92) with 
no statistically significant difference in severe AECOPD(IRR, 0.86; 95% CI, 0.63-1.18) (Fig 2). Sensitivity
analyses produced similar results (Table 3). When
considering only exacerbations during the first year of
follow-up among the sample of matched participants
who had accrued at least 1 year of follow-up (n ¼ 788),
aspirin users had a 30% lower incidence rate of total
AECOPD (IRR, 0.70; 95% CI, 0.52-0.96), 37% lower
incidence of moderate AECOPD (IRR, 0.63; 95% CI,
0.45-0.88) but no association with severe AECOPD
(IRR, 1.02; 95% CI, 0.62-1.68 (Fig 2).
Subgroup Analyses
In the propensity score-matched sample, comparing
aspirin users and nonusers, the prevalence of baseline
chronic bronchitis (47% vs 47%), severe COPD
(32% vs 31%), total emphysema $ 5% (56% vs 56%),
and cardiometabolic phenotype (39% vs 37%) was
similar. In stratified analysis aspirin use was more
strongly associated with total AECOPD among
participants with chronic bronchitis (IRRCBþ, 0.66;
95% CI, 0.51-0.86; Pinteraction ¼ .04) (Fig 3). This finding
was reflected in moderate AECOPD (IRRCBþ, 0.62;
95% CI, 0.47-0.83; IRRCB–, 0.96; 95% CI, 0.72-1.29;
Pinteraction ¼ .04) but not severe AECOPD (IRRCBþ, 0.73;
95% CI, 0.48-1.13; IRRCB–, 1.1; 95% CI, 0.69-1.74;
Pinteraction ¼ .2). There was no effect modification by
COPD severity (Pinteraction ¼ .3), presence of emphysema
(Pinteraction ¼ .6), emphysema severity (Pinteraction ¼ .4),
or cardiometabolic phenotype (Pinteraction ¼ 1) (Fig 3).
Association of Aspirin Use With Respiratory
Symptoms and Quality of Life
A total of 1,044 participants were matched for the cross-
sectional analysis at baseline. Because of missing
outcome data, 66 participant pairs were excluded from
the SGRQ analysis, as were 9 pairs from the mMRC
analysis, 55 pairs from the CAT analysis, and 62 pairs
from the 6MWD analysis. Aspirin users had SGRQ
scores that were on average 3 points lower than those of
nonusers (95% CI, –4.9 to –1.1), had 34% lower odds of
reporting moderate-severe dyspnea based on mMRC
score $ 2 (adjusted OR, 0.66; 95% CI, 0.49-0.90), and
lower total CAT score (b, –1.1; 95% CI, –1.9 to –0.2).
There was no association between aspirin use and
6MWD (b, 0.7 m; 95% CI, –14.3 to 15.6).
Discussion
Daily aspirin use in a large stable COPD cohort was
associated with reduced incidence rate of AECOPD
during 3 years of follow-up, as well as better quality of
life and less dyspnea in cross-sectional analysis at
TABLE 1 ] Baseline Characteristics
Characteristic















(n ¼ 503) P Value
Age, mean  SD 67.5  6.8 63.5  8.4 < .0001 66.5  6.8 66.5  7.6 1
Female 270 (35.3) 450 (48.2) < .0001 210 (41.8) 208 (41.4) .9
Race: black 80 (10.5) 167 (17.9) < .0001 63 (12.5) 60 (11.9) .8
Less than high school education 267 (35) 386 (41.3) .007 189 (37.6) 196 (39) .6
FEV1 % predicted
(postbronchodilator)
63.1  22.6 59.7  23.2 .003 62.4  23.2 61.7  22.9 .7
Current smoker 206 (27) 363 (38.9) < .0001 155 (30.8) 150 (29.8) .7
Cigarettes/d among current
smokers, median (Q1-Q3)
12 (6-20) 15 (8-20) .05 10.5 (6-20) 15 (7-20) .2
Supplemental home oxygen 182 (23.8) 212 (22.7) .6 115 (22.9) 118 (23.5) .8
Percent emphysema on MDCT scan,
mean  SD
10.5  10.7 11.8  11.8 .02 11.0  11.4 10.6  10.7 .5
Emphysema $ 5% on MDCT scan 423 (55.9) 549 (59) .2 282 (56.3) 280 (55.9) .9
Anemia: hemoglobin < 13 g/dL
(males) or < 12 g/dL (females)
84 (11) 69 (7.4) .01 41 (8.2) 52 (10.3) .2
Hypertension 477 (62.4) 382 (40.9) < .0001 280 (55.7) 274 (54.5) .7
Coronary arterial disease 239 (31.3) 88 (9.4) < .0001 79 (15.7) 83 (16.5) .7
Congestive heart failure 38 (5) 15 (1.6) < .0001 13 (2.6) 13 (2.6) 1
Stroke 39 (5.1) 35 (3.8) .2 25 (5) 22 (4.4) .7
Diabetes 153 (20) 80 (8.6) < .0001 75 (14.9) 71 (14.1) .7
Statin use (prior 3 mo) 433 (56.7) 246 (26.3) < .0001 216 (42.9) 213 (42.4) .8
b-Blocker use (prior 3 mo) 231 (30.2) 106 (11.4) < .0001 83 (16.5) 96 (19.1) .3
Inhaled corticosteroid
use (prior 3 mo)
338 (44.2) 452 (48.4) .09 235 (46.7) 247 (49.1) .4
Long-acting bronchodilator




95 (12.4) 108 (11.6) 59 (11.7) 55 (10.9)
Long-acting b-agonist (LABA) 138 (18.1) 194 20.8) 97 (19.3) 106 (21.1)
Both LAMA and LABA 199 (26.1) 249 (26.7) 132 (26.2) 134 (26.6)
Neither LAMA nor LABA 332 (43.5) 383 (41) 215 (42.7) 208 (41.4)
Body mass index, mean  SD 28.1  5.2 26.7  5.2 < .0001 27.8  5.2 27.6  5.2 .5
Underweight (< 18.5 kg/m2) 18 (2.4) 42 (4.5) < .0001 13 (2.6) 12 (2.4) .9
Normal or overweight
(18.5 to < 30 kg/m2)
474 (62) 651 (69.7) 326 (64.8) 332 (66)
Obese ($ 30 kg/m2) 272 (35.6) 241 (25.8) 164 (32.6) 159 (31.6)
Propensity score, mean  SD 0.57  0.22 0.35  0.19 < .0001 0.47  0.18 0.47  0.18 .8
MDCT ¼ multidetector row CT; Q1, Q3 ¼ quartiles 1 and 3; SPIROMICS ¼ Subpopulations and Intermediate Outcome Measures in COPD Study. Boldface
entries indicate a statistically significant difference, with a P value less than .05.baseline. In subgroup analysis aspirin use was more 
strongly associated with reduced incidence of AECOPD 
among participants reporting symptoms of chronic 
bronchitis at baseline. Although aspirin use has 
previously been linked with reduced mortality risk inpatients with COPD, to our knowledge this is the first
study to investigate the association of daily aspirin use
with respiratory morbidity in COPD. These findings
imply that aspirin may reduce the risk of respiratory
morbidity and improve symptoms in COPD.
TABLE 2 ] Crude COPD Exacerbation Rates by Aspirin









(Mean  SD) P Value
Total
exacerbations
0.51  0.86 0.65  1.1 .03
Moderate
exacerbations
0.34  0.63 0.44  0.82 .02
Severe
exacerbations
0.17  0.47 0.20  0.63 .4In the absence of data from a randomized controlled
trial, this study allows evaluation of aspirin use in COPD
while attempting to minimize the influence of
confounding by indication. The reduced incidence of
total and moderate AECOPD among aspirin users was
independent of concurrent respiratory or cardiovascular
medication use and robust when analyzing the entire
follow-up period, limiting the analysis to the first year of
follow-up, and across all sensitivity analyses. There was
no association between aspirin use and incidence of
severe AECOPD requiring ED visit or hospitalization.
This may be a consequence of few severe AECOPD
during the study, which limits the power to detect a
difference, or the higher prevalence of respiratory viral
infections, which are more likely to lead to
hospitalization for AECOPD33 and would not be
augmented by aspirin therapy.
Four previous studies have reported reduced all-cause
mortality among aspirin users with stable COPD8,12 and
following AECOPD,9,10 while two found no such
association.13,14 Meta-regression analysis by Pavasini










Figure 2 – Association of aspirin use with incidence rate of acute exacerbatimortality without modification by smoking status, sex,
cardiovascular comorbidities, or use of other
cardiovascular medications. Findings of this study add
to the existing literature by highlighting that aspirin use
is also associated with reduced respiratory morbidity
across several domains—including exacerbation risk,
quality of life, and dyspnea—factors related to patient
well-being and health-care utilization. Notably, however,
the difference in SGRQ and CAT scores between aspirin
users and nonusers at baseline (3 and 1.1, respectively),
while statistically significant, did not reach the minimal
clinically important difference of these surveys (4 and 2,
respectively)34,35; although similar effect sizes have been
reported in most studies evaluating mean SGRQ
difference with long-acting muscarinic antagonist36 and
long-acting b-agonist.37,38
COPD phenotyping in this study allows for the
identification of subgroup effects that inform future
studies. It appears that participants who reported cough
and phlegm at baseline, consistent with the chronic
bronchitis phenotype that has been associated with
greater risk for morbidity and mortality,39 had a
significantly stronger association between aspirin use
and reduced AECOPD. On the basis of the findings of
this study, future studies investigating aspirin therapy in
COPD may benefit from oversampling participants with
the chronic bronchitis phenotype. There was a trend
toward stronger association between aspirin use and
AECOPD among participants with mild or moderate
COPD compared with those with severe COPD. While
this may be due to a higher proportion of severe rather
than moderate AECOPD in the severe COPD group
(36% vs 28% of total exacerbations, respectively), it may











TABLE 3 ] Sensitivity Analyses
Analysis Method No. Total AECOPD Moderate AECOPD Severe AECOPD
Primary propensity-matched analysis
(main analysis)
1,008 0.78 (0.65-0.94) 0.75 (0.61-0.92) 0.86 (0.63-1.18)
Fully adjusted unmatched sample 1,698 0.81 (0.70-0.95) 0.78 (0.65-0.94) 0.91 (0.71-1.18)
Bivariate analysis adjusting for propensity
score
1,698 0.78 (0.67-0.92) 0.77 (0.63-0.93) 0.86 (0.66-1.11)
Inverse probability of the treatment weights 1,698 0.71 (0.62-0.82) 0.66 (0.56-0.78) 0.88 (0.71-1.10)
AECOPD ¼ acute exacerbation of COPD.the severe COPD group due to inadequate power. There
was no difference in the association of aspirin use with
AECOPD, based on the presence or burden of
emphysema at baseline. Emphysema progression, which
was attenuated by aspirin use in a recent study,15 could
not be evaluated due to lack of follow-up MDCT scans.
Aspirin has both systemic and local pulmonary
mechanisms of action that may explain these study
findings including inactivation of platelets and reduced
inflammation. A urinary metabolite of thromboxane A2,
which is secreted by activated platelets, has been shown
to be elevated among patients with COPD and
represents the pathway irreversibly blocked by
aspirin.40,41 Circulating inflammatory markers IL-6 and
C-reactive protein, when persistently elevated, may
represent a systemic inflammatory phenotype of COPDCardiometabolic Phenotype




2+ Comorbidities 383 (38)
623 (62)<2 Comorbidities
At least 5% 558 (56)
440 (44)Less than 5%





Figure 3 – Association of aspirin use with incidence of COPD exacerbations
presence of emphysema ($ 5%), and presence of cardiometabolic phenotype
Disease; MDCT ¼ multidetector row CT; P-int ¼ P value for interaction wiand are attenuated by aspirin in other patient
populations.42,43 Furthermore, treatment with aspirin
reduced proinflammatory cytokines in bronchoalveolar
lavage samples from 33 healthy volunteers.44
This study has several limitations. Aspirin use was
ascertained through self-report, a potential source of
measurement error. Aspirin dose was unavailable and
therefore a dose effect could not be investigated. In
addition, duration of aspirin use and adherence to
therapy before and during the study were unavailable,
which limits inferences regarding baseline symptoms
and may lead to uncaptured therapeutic crossover
during follow-up. AECOPD were not routinely
adjudicated using medical records in this study, which
may lead to misclassification of events. Mild AECOPD,









, based on presence of chronic bronchitis at baseline, COPD severity,
at baseline. GOLD ¼ Global Initiative for Chronic Obstructive Lung
th aspirin use.
of inhaler medications without health-care utilization,
oral corticosteroid, or antibiotic initiation, were not
systematically ascertained in this study and therefore the
association of aspirin use with mild AECOPD was not
investigated. SPIROMICS was not specifically designed
to address aspirin use in COPD, and despite the use of
statistical methods such as propensity score matching to
minimize confounding by indication and residual
confounding, observational studies remain vulnerable to
bias due to inability to completely control for both
measured and unmeasured factors relating to
individuals, their providers, and the health-care system.
For example, aspirin users may represent participants
with higher health literacy who take measures to protect
against exacerbations that were not ascertained in this
study such as increased physical activity, avoidance of
environmental exposures or sick contacts, and
adherence to vaccinations or medications. Arandomized controlled study is necessary to establish
whether a direct causal effect exists between aspirin use
and AECOPD. Finally, reported AECOPD may
represent cardiovascular events that are clinically
misclassified; however, the presence of cardiovascular
risk factors did not modify the association between
aspirin use and AECOPD.Conclusions
In conclusion, on the basis of findings from a large
multicenter observational cohort, daily aspirin use at
baseline was associated with lower incidence rate of
AECOPD, as well as less severe respiratory symptoms
and better quality of life at baseline. Prospective
randomized clinical trials of aspirin use are warranted to
explore its potential effectiveness in reducing COPD
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